BlueCross BlueShield
Federal Employee Program

**LORBRENA**
**(lorlatinib)**

# Pre - PA Allowance

None

---

# Prior-Approval Requirements

**Age** 18 years of age or older

**Diagnosis**

Patient must have the following:

Metastatic non-small cell lung cancer (NSCLC)

**AND ALL** of the following:

1. Anaplastic lymphoma kinase (ALK)-positive as detected by and FDA-approved test
2. Prescriber agrees to monitor the following:
    a. ECG
    b. Serum cholesterol and triglycerides
3. Females of reproductive potential **only**: patient will be advised to use effective non-hormonal contraception during treatment with Lorbrena and for 6 months after the final dose
4. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Lorbrena and for 3 months after the final dose

# Prior - Approval Limits

**Quantity**

| Strength | Quantity |
|---|---|
| 25 mg | 270 tablets per 90 days **OR** |
| 100 mg | 90 tablets per 90 days |

**Duration** 12 months

---

# Prior – Approval *Renewal* Requirements

**Age** 18 years of age or older

**Diagnosis**

BlueCross BlueShield
Federal Employee Program

**LORBRENA**
**(lorlatinib)**

Patient must have the following:

Metastatic non-small cell lung cancer (NSCLC)

**AND ALL** of the following:

1. **NO** disease progression or unacceptable toxicity
2. Prescriber agrees to monitor the following:
    a. ECG
    b. Serum cholesterol and triglycerides
3. Females of reproductive potential **only**: patient will be advised to use effective non-hormonal contraception during treatment with Lorbrena and for 6 months after the final dose
4. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Lorbrena and for 3 months after the final dose

## Prior - Approval *Renewal* Limits

Same as above